Because KRAS and BRAF mutations are mutually exclusive in cancer, Kim et al. explored the difference in gene expression between the two mutant groups in colorectal cancer cell lines [54], which would be useful to classify responder/non-responders for RAS or BRAF inhibitors. Here, KRAS is linked to cancer.